June 12, 2023

TherageniX, an NLC venture, delivers genes for tissue repair and regeneration

Disease, injuries and aging can damage body tissues. There is an unmet need for novel therapies to enable tissue repair and regeneration. The use of gene therapy to provide biological cues to boost the body’s response has been shown to aid regeneration of skin, bone, muscle and cartilage. TherageniX, another venture from NLC, delivers genes which can instruct the body to regenerate tissues

While any tissue can be targeted through the technology, TherageniX will initially focus on orthopedic applications, with the ambition of improving the outcomes for patients with bone loss, infection and disease. The transplantation of autologous bone is the gold standard bone repair strategy. However, this process has drawbacks in terms of limited availability of autologous bone for large defects, particularly in patients with diseased bone. There is ultimately insufficient regenerative capacity, and many bone implants fail due to poor integration, infection, or do not provide satisfactory functionality. 

TherageniX’s innovative solution will augment autologous bone grafts intraoperatively by delivering gene(s) of interest using a proprietary non-viral delivery system. The approach will improve regenerative capacity of the graft and is expected to lead to better functional outcomes, while reducing additional trauma at the donor site. 

The new therapy has additional benefits in terms of reduced waiting time for patients, reduced manufacturing costs and the possibility to provide an off-the-shelf solution. The intraoperative nature also makes it simpler and cost effective compared to other approaches requiring cell expansion that are laborious and capital intensive.

Anandkumar Nandakumar, CEO of TherageniX: ‘‘We have a unique approach to help patients with bone defects. We are only at the first step with the possibilities of this technology. In the future, we can envision treating several types of defects and tissues and move towards personalized medicine.’’

Anandkumar has several years’ experience in medtech, biotechnology, start-ups and scale-ups and a strong scientific connection to bone tissue engineering. His passion stems from working on products that make patients’ lives better and address unmet needs. 

The patented technology is a combination of a proprietary non-viral delivery system with desired regenerative factor genes (e.g. VEGF and BMP; for vascularization and osteogenesis, respectively) and autologous bone marrow cells from the patient. The technology was developed by Dr. James Dixon and colleagues at the University of Nottingham  School of Pharmacy and has been licensed to TherageniX. Dr. Dixon is a cell and molecular biologist, with specific expertise in intracellular delivery systems for the treatment of disease. TherageniX is excited to collaborate with Dr  Dixon’s group to improve the science and technology further and to translate this work into therapies for patients.

Dr.  Dixon commented: “Adapting our technology for a rapid application directly on grafts in the operating theatre has been a vision for our gene delivery platform. We hope that our system will generate a platform of transformative, economically viable and impactful approaches to clinical problems that remain poorly addressed in modern medicine.”

TherageniX is an early-stage venture with the first proof-of-concept in pre-clinical studies and is keen on further developing this technology and bringing it to the clinic.


About NLC
NLC is the leading European healthtech venture builder. NLC identifies top-notch early-stage healthcare inventions and brings them to market, acting as the connecting link between technology innovation and entrepreneurship in medtech, biotech and digital health. To optimize patient care and enhance its positive and sustainable impact, NLC collaborates with corporates such as Philips and healthcare and academic research institutions such as Oxford University and Mayo Clinic.

NLC is a certified B Corp and supports UN Sustainable Development Goals 3, 9, 17. With its growing team of more than 80 professionals and over 110 portfolio ventures built across 11 European countries, NLC is currently expanding its impact-driven operations to the US and the Gulf region.



NLC – The European Venture Builder
Anne Reijns
Marketing & Communications Lead

Anandkumar Nandakumar| CEO 

NLC Health Ventures Footer